Results from a new study in patients with early Alzheimer’s disease showed a short course of intravenous immune globulin slows the disease’s progression.
A Phase II clinical trial that is testing the success of a pancreatic cancer vaccine is giving researchers hope that the treatment might be ready for wide distribution within the next couple of years.
VARIZIG, a hyperimmune globulin indicated for post-exposure prophylaxis of varicella zoster virus (VZV) in high-risk patients, has been approved by the U.S.Food and Drug Administration.
Under the Affordable Care Act (ACA),the health insurance sales tax and age-rating restrictions will increase premiums for many, according to a report by Oliver Wyman, a management consulting firm.
The U.S. Food and Drug Administration has approved a new children’s vaccine that targets two common causes of bacterial meningitis.
Octapharma USA’s Octaplas, a solvent/detergent-treated pooled human plasma, has been approved by the U.S. Food and Drug Administration.
A recent survey conducted by the U.S. Centers for Disease Control and Prevention shows that the number of provider sites participating inimmunization information systems has increased.
New study results suggest that treatment with Privigen (ImmuneGlobulin Intravenous [Human], 10%Liquid), an intravenous immunoglobulin(IVIG), may lead to improvement in function in patients with chronic inflammatory demyelinating polyneuropathy.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is recommending the expanded use of Pfizer’s Prevnar 13 vaccine.
New research demonstrates how dying or damaged brain cells release debris into the bloodstream and give rise to specific autoantibodies that appear to be reliable biomarkers for early diagnosis of Alzheimer’s and other neurodegenerative diseases.
U.S. Food and Drug Administration researchers have discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.
Researchers at the Scripps ResearchInstitute in La Jolla, Calif., have developed a vaccine that may one day protect people against the addictive effects of nicotine.
